MedTrace Logo

Teaching Inhaler Use With the INCA Device in a Community Pharmacy Setting

NCT02203266 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2019-07-18

No results posted yet for this study

Summary

The purpose of this trial is to discover whether providing feedback to patients from a device that records when and how well a patient uses a Seretide Diskus inhaler will lead to:

* Improved compliance with prescribed inhaler use
* Improved technique of inhaler use
* A reduction in respiratory health related outcomes caused by poor inhaler compliance and usage.
* An improvement in patient quality of life scores

Conditions

  • Asthma
  • Pulmonary Disease, Chronic Obstructive

Interventions

DEVICE

Feedback

Feedback on the patient's own inhaler use, with personalized information on the patients technique and timing of use of the diskus inhaler as recorded on the INCA device will be provided to patients in the feedback group after 1,2 and 6 months.

BEHAVIORAL

Education

Feedback on the patient's own inhaler technique as observed by pharmacist and education to support best use will be provided to patients in the demonstration group after 1,2 and 6 months.

Sponsors & Collaborators

  • Royal College of Surgeons, Ireland

    collaborator OTHER

  • Beaumont Hospital

    lead OTHER

Principal Investigators

  • Richard Costello, Professor · Royal College of Surgeons in Ireland, Clinical Research Centre, Beaumont Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2016-12-31
Completion
2017-01-31

Countries

  • Ireland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02203266 on ClinicalTrials.gov